STAT Plus: Stunning FDA rejection signals potential new hurdles for gene therapies
ADOBE
The rejection of a gene therapy for the bleeding disorder hemophilia potentially complicates the path to market for these one-time treatments.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario